Article ; Online: A provisional evaluation of Australia's medical cannabis program.
The International journal on drug policy
2023 Volume 122, Page(s) 104210
Abstract: In 2016, the Australian Government legislated to allow cannabis to be prescribed to patients as an unapproved medicine under the special access provisions of the Therapeutic Goods Act. This paper compares the Australian regulatory approach with other ... ...
Abstract | In 2016, the Australian Government legislated to allow cannabis to be prescribed to patients as an unapproved medicine under the special access provisions of the Therapeutic Goods Act. This paper compares the Australian regulatory approach with other national approaches, outlines the main provisions of the Special Access Scheme for medical cannabis, describes how the program has evolved since 2017, includes an analysis of adverse events reported to the Therapeutic Goods Administration, and discusses the barriers that remain for patients who wish to access medical cannabis. It assesses how well the Australian program has addressed the challenges of providing patients with easier access to medical cannabis while ensuring that high-quality products are used safely and effectively under medical guidance. |
---|---|
MeSH term(s) | Humans ; Medical Marijuana/adverse effects ; Australia ; Cannabis ; Pharmaceutical Preparations ; Government |
Chemical Substances | Medical Marijuana ; Pharmaceutical Preparations |
Language | English |
Publishing date | 2023-10-07 |
Publishing country | Netherlands |
Document type | Journal Article |
ZDB-ID | 2010000-0 |
ISSN | 1873-4758 ; 0955-3959 |
ISSN (online) | 1873-4758 |
ISSN | 0955-3959 |
DOI | 10.1016/j.drugpo.2023.104210 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.